Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Better Buy: Pfizer vs. GlaxoSmithKline

TheMotleyFool

0 0

Pharma giants Pfizer (NYSE: PFE) and GlaxoSmithKline (NYSE: GSK) share similar visions for the future. Both aim to transform into smaller, nimbler biopharmaceutical outfits focused on high-value R&D. Last year, investors witnessed the strategy begin to take shape at both businesses.

Image source: Getty Images.

In August 2019, Pfizer and Glaxo completed the combination of their consumer healthcare businesses into a new joint venture. The unit operates under the GSK Consumer Healthcare name, with Glaxo holding a 68% majority stake. The operation boasts the largest global portfolio of over-the-counter medicines, vitamins, minerals, and supplements.

Source Fool.com

Like: 0

PFE

Share